Pregabalin Capsule
Product Images NDC 72162-1543

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621543)

Label for Pregabalin Capsules 75 mg, an oral prescription drug. The label shows the product name, strength, and quantity of 90 capsules. It includes storage information and warnings, the NDC number 72162-1543-2, repackager Bryant Ranch Prepack, and manufacturer ScieGen Pharmaceuticals. The label features a barcode and a QR code.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart showing the percent of patients improved relative to the percent improvement in pain from baseline. It compares pregabalin at doses of 200 mg, 100 mg, and 25 mg three times a day, plus placebo. The y-axis is percent of patients improved, ranging from 0 to 100%, and the x-axis is percent improvement in pain.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph displaying percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day with placebo, showing two distinct curves representing each treatment group's pain improvement outcomes.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph depicts higher improvement percentages associated with higher doses of Pregabalin.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares pain improvement outcomes across these treatments using three distinct lines.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart showing responder rates (%) from two clinical studies, Study E1 and Study E3, comparing various doses of Pregabalin to placebo. The chart displays responder rates across different dosages with labels for sample sizes (N) at the bottom. An asterisk indicates statistically significant differences versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A chart depicting seizure reduction as median percentage change from baseline versus dose in mg/day for Pregabalin across four studies (E1 BD, E2 TID, E3 BD, E3 TID). The graph shows increasing seizure reduction with higher doses, annotated with significant p-values.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart comparing the percent improvement in pain from baseline against the percent of patients improved, for Pregabalin dosages of 300 mg, 450 mg, and 800 mg daily doses, and a placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved, with separate lines for each treatment group.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over a 180-day period for Pregabalin versus placebo. The graph shows Pregabalin with a solid line and placebo with a dashed line, illustrating a higher percentage of subjects without LTR over time for Pregabalin compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 (BOCF) between Pregabalin and placebo. The x-axis represents the percent improved from baseline to week 12, ranging from 0 to 100. The y-axis shows the percent of subjects improved, ranging from 0% to 100%. The solid line represents Pregabalin, showing higher improvement percentages across the range, while the dashed line represents placebo with consistently lower percentages of improvement.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart depicting the percent of subjects improved on the vertical axis against percent improved from baseline to week 16 on the horizontal axis. Two lines represent Pregabalin and Placebo groups, showing higher improvement percentages for Pregabalin across the range. The chart illustrates comparative subject improvement over time.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for creatinine clearance (CLcr) calculation based on age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin showing its molecular arrangement including amine and carboxylic acid functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.